ClinicalTrials.gg
RecruitingNCT02208388PERFUSERCTUpdated Apr 5, 2023

Prospective Evaluation of MyocaRdial PerFUSion ComputEd Tomography Trial

An interventional study of computed tomography perfusion guided treatment and Fractional flow reserve guided treatment in Coronary Disease, sponsored by Young-Hak Kim, MD, PhD. Recruiting at 7 sites in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2023-04-05.

Sponsored by Young-Hak Kim, MD, PhD · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2014; still recruiting 12 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies in Coronary Disease with a site in Korea, Republic of — 6 open to participants now, 7 under way, none of them phase 3. Coronary Disease · Korea, Republic of.

Planned enrollment
15th of 29
1,000 · median 1,000
Started
2014
with 4 others
No phase
7 of 49
2 open now
Registered
28th of 49
by date

Among the 49 studies in Coronary Disease with a site in Korea, Republic of, this one is the 15th largest by planned enrollment of the 29 interventional ones that give a count, is one of 5 that started in 2014, is one of 7 with no phase, and was the 28th registered.

Coronary Disease

1,522 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.

Browse Coronary Disease studies →

Open to participants now

6 of the 49 studies in Coronary Disease with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Coronary Disease with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate safety and effectiveness of CTP(computed tomography perfusion) guided revascularization vs FFR(Fractional flow reserve) guided revascularization

03

Conditions studied

  • Coronary Disease

Browse trials for

Keywords

  • Computed tomography perfusion
  • Fractional flow reserve
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 20 and more
  • Diagnosed angina or angina equivalent symptom or positive exercise treadmill test
  • Patients with intermediate- or high-risk probability of CAD defined by Diamond and Forester
  • 70 % stenosis or more in coronary CTA
  • Willing to provide informed, written consent

Exclusion criteria

Exclusion Criteria:

  • Requirement for surgical procedure
  • Cardiogenic shock and/or need for mechanical/pharmacologic hemodynamic support
  • Recent STEMI (\<5 days)
  • Non STEMI, if the cardiac troponin is not stable or starting to decline
  • \<30%
  • \<2 years
  • Impaired renal function with an effective less than 30mL/min/1.73 ㎡ or creatinine more than 2.0 mg/dL
  • Undergoing evaluation for organ transplantation
  • Participation or planned participation in another cardiovascular clinical trial
  • Pregnancy
  • Inability to take dual antiplatelet therapy for six months
  • Previous CABG
  • Left main disease requiring revascularization
  • Any target lesion with in-stent restenosis
  • class 3 or 4a
  • Severe and persistent angina with severe limitation in everyday living activities (Canadian Cardiovascular Society grading Class IV)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
1,000 participants (estimated)

Study arms

  • Experimental
    Computed tomography perfusion

    Patients with Computed tomography perfusion

    Device: computed tomography perfusion guided treatment

  • Active comparator
    Fractional flow reserve

    Patients with Fractional flow reserve

    Device: Fractional flow reserve guided treatment

Interventions

  • Devicecomputed tomography perfusion guided treatment
  • DeviceFractional flow reserve guided treatment
06

What researchers measure

Primary outcomes

  1. Composite Events

    All cause death, Myocardial infarction, Diseased-related unplanned hospitalization or stroke

    Time frame: 1 year

Secondary outcomes

  1. All cause death

    All cause death

    Time frame: 5 year

  2. Myocardial infarction

    Myocardial infarction

    Time frame: 5 year

  3. Target vessel revascularization

    Target vessel revascularization

    Time frame: 5 year

  4. Stent thrombosis

    Stent thrombosis

    Time frame: 5 year

  5. Seattle Angina Questionnaire,EQ5D questionnaire

    Quality of life score assessed by the EQ-5D-5L The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. Higher score of EQ-5D and EQ VAS means the low quality of life. EQ-5D: the minimum and maximum values are 5 and 25 respectively. EQ VAS: the minimum and maximum values are 0 and 100 respectively. Seattle Angina Questionnaire The Seattle Angina Questionnaire (SAQ) is a vali- dated disease-specific instrument for assessing the health status of patients with coronary artery disease. SAQ scores can be aligned with clinical constructs (eg, scores on the SAQ angina frequency scale of 0-30 points indicate daily angina, 31-60 points indicate weekly angina, 61-99 points indicate monthly angina, and 100 points indicate no angina)

    Time frame: 5 year

  6. Success of intervention

    Defined as mean lesion diameter stenosis ≤50% and without the occurrence of in-hospital myocardial infarction (MI), target vessel revascularization (TVR), or death

    Time frame: 5 year

  7. Cost effective analysis

    Cost effective analysis

    Time frame: 1 year

07

Study locations

2 of 7 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2014 (actual). Primary completion is estimated for Mar 2028, 162 months after the start.

Of 180 non-industry interventional studies with no phase under Coronary Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 162 months is above that.

Counting every sponsor, half of 202 studies reached it within 25 months; a quarter within 14 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2014
First posted
Aug 5, 2014
StartActual
Aug 12, 2014
Primary completionEst.
Mar 5, 2028
CompletionEst.
Mar 5, 2028
Last update
Apr 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02208388
Lead sponsor
Young-Hak Kim, MD, PhD
Responsible party
Young-Hak Kim, MD, PhD (MD, Asan Medical Center) — Sponsor-investigator
First posted
Aug 5, 2014
Start date
Aug 12, 2014
Primary completion
Mar 5, 2028 (estimated)
Completion
Mar 5, 2028 (estimated)
Last update
Apr 5, 2023

Study contacts

Young-Hak Kim, MD
Contact
mdyhkim@amc.seoul.kr
Byoung-Wook Choi, MD
principal investigator · Severance Hospital, Yonsei University College of Medicine
Young-Hak Kim, MD
principal investigator · Asan Medical Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion